News

Novo Nordisk halts Wegovy sales on Hims & Hers, claiming "deceptive marketing" practices
Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the ...
Novo Nordisk ends collaboration with Hims & Hers for discounted weight loss meds
Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for patients who have a prescription for the medication but no insurance coverage ...
Novo Nordisk Abruptly Ends Partnership with Hims, Claiming ‘Sham Compounding’ GLP-1 Drugs
The pharmaceutical company alleges Hims is widely selling cheaper versions of its blockbuster drugs, despite the FDA's recent ...
Daily Voice on MSN17h
Plainsboro-Based Wegovy Provider Ends Hims & Hers Deal Over Knockoff Weight-Loss Drug Sales
Novo Nordisk has ended its partnership with Hims & Hers Health after two months, accusing the telehealth company of pushing ...
StockStory.org on MSN16h
Hims & Hers Health (HIMS) Stock Trades Down, Here Is Why
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 29.2% in the morning session after Novo Nordisk, the maker ...
Zacks Investment Research on MSN4d
Hims & Hers Stock Jumps 85.1% in 3 Months: Is It a Buy Now?
Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term gains from the stock lately despite its ...
Hims & Hers Health (NYSE:HIMS) Reports Q1 2025 Earnings Doubling Sales & Net Income
Hims & Hers Health (NYSE:HIMS) recently announced the introduction of affordable access to Wegovy, a significant move aimed at improving obesity treatment options. This, along with strong Q1 2025 ...